Nadeen Ibrahim, Leanne Yinusa-Nyahkoon, Erica Holland
{"title":"Perspectives and Preferences of Patients With Substance Use Disorder on Urine Toxicology Testing in Pregnancy.","authors":"Nadeen Ibrahim, Leanne Yinusa-Nyahkoon, Erica Holland","doi":"10.1097/ADM.0000000000001800","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001800","url":null,"abstract":"<p><strong>Objectives: </strong>Urine toxicology testing is a ubiquitous practice in pregnancy among patients with substance use disorder (SUD). However, little data exists on patient views of this consequential practice. We aimed to explore the perspectives of patients with SUD on the utility of urine toxicology testing in pregnancy and on toxicology processes to inform best practice.</p><p><strong>Methods: </strong>We conducted semistructured interviews with 15 pregnant and postpartum patients with SUD receiving care at an urban interdisciplinary obstetric and SUD clinic. Interviews explored patient experiences with urine toxicology testing, perceptions of risks and benefits, and opinions on optimal testing practices, including perspectives on a recently implemented toxicology testing policy. Interviews were recorded, transcribed, and analyzed using a combined deductive-inductive methodology to identify themes.</p><p><strong>Results: </strong>Participants supported urine toxicology testing as an accountability tool but expressed concerns about testing inaccuracy and its potential legal consequences. Many participants felt that confirmatory testing and a transparent, comprehensive consent process could mitigate these challenges. Experiences in a specialty SUD treatment program helped reduce testing stigma and improved overall care. The newly implemented urine toxicology testing policy, which included a detailed consent process, contrasted favorably with prior experiences of urine toxicology testing, where consent was often implied or incomplete.</p><p><strong>Conclusions: </strong>Clinicians and policymakers considering urine toxicology testing practice changes during pregnancy should consider patient perspectives and preferences as they work to optimize health for patients and their families.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren Oshman, Shelby Anderson, Dongru Chen, Christopher J Frank
{"title":"Variation in Prenatal and Newborn Toxicology Testing Policies in Michigan Hospitals.","authors":"Lauren Oshman, Shelby Anderson, Dongru Chen, Christopher J Frank","doi":"10.1097/ADM.0000000000001802","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001802","url":null,"abstract":"<p><strong>Objectives: </strong>This study examines hospital policies on prenatal and newborn toxicology testing, and subsequent referral to child protective services (CPS) for suspected abuse and neglect in Michigan. We assessed variability between hospitals, alignment with state law, and consistency with professional guidelines.</p><p><strong>Methods: </strong>This cross-sectional survey was conducted between February 1, 2024, and September 1, 2024. All 76 birth hospitals in Michigan were invited to participate. The 10-question survey addressed hospital protocols for prenatal and newborn toxicology testing, indications for testing in risk-based protocols, informed consent policies, protocols for reporting to child protective services, and specific policies for cannabis exposure and patients receiving medication treatment for opioid use disorder.</p><p><strong>Results: </strong>Of 76 birth hospitals in Michigan, 25 completed the survey (response rate 33%). Hospitals reported variability in prenatal and newborn toxicology testing policies. Of respondents, 28% (7/25) reported universal prenatal toxicology testing and 68% (17/25) reported risk-based testing. Most hospitals (23/25) used a risk-based testing strategy for newborns. The most common risk-based indication was no prenatal care (12/17). Although guidelines recommend informed consent for all prenatal toxicology tests, only 56% (14/25) of hospitals required informed consent for prenatal toxicology testing and only 20% (5/25), required informed consent from a parent for newborn toxicology testing.</p><p><strong>Conclusions: </strong>Variability in hospital prenatal and newborn toxicology testing policies, even within a single state's regulatory framework, highlights opportunities for quality improvement at the level of hospital policy to improve the ethical treatment of birth parents and newborns with potential exposures to substance use during pregnancy.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Locked Out or Linked Up: Lessons in Cross-agency Data Linkage and a Call for State-based Measures for Substance Use Surveillance.","authors":"Jake R Morgan, Sona Fokum","doi":"10.1097/ADM.0000000000001805","DOIUrl":"10.1097/ADM.0000000000001805","url":null,"abstract":"<p><p>As the durability of federal public health surveillance is called into question, state and local health departments are increasingly central to monitoring the overdose crisis. From interviews with stakeholders leading data linkage initiativesin 7 states, we identified pragmatic strategies for building capacity, including legislative mandates paired with funding and privacy safeguards, academic-government partnerships, and visible champions who build cross-agency trust. Two categories of opportunities emerged: linking person-level data across agencies within states and standardizing measures across states. Standardization of local addictions surveillance measures is critical for both local quality improvement and national benchmarking, and we propose the proportion of nonfatal overdoses followed by treatment as a first shared metric and offer actionable steps for advancing substance use surveillance locally.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anthony M Kendle, Mykenzie King, Margaret Cornwall, Tanner G Wright, Kristin Kosyluk
{"title":"Assessment of Health Care Worker Stigma Toward Pregnant People With Opioid Use Disorder.","authors":"Anthony M Kendle, Mykenzie King, Margaret Cornwall, Tanner G Wright, Kristin Kosyluk","doi":"10.1097/ADM.0000000000001787","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001787","url":null,"abstract":"<p><strong>Objectives: </strong>Stigma within health care can negatively affect pregnancy outcomes. Prior vignette studies suggest stigma varies by treatment status, but this has not been examined among pregnant people with opioid use disorder (OUD). We aimed to assess public stigma among health care workers toward pregnant people with OUD receiving medication for OUD (MOUD) versus actively using opioids and examine differences by clinical role and specialty.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey of staff (residents/fellows, clinicians, nurses, clinical support staff, ancillary staff, and medical students) solicited through email and public postings at a tertiary care hospital from May to November 2023. Eligible participants were 18 years or older and worked in roles interacting with pregnant patients. Participants were randomized to 1 of 2 vignettes describing a pregnant patient with OUD receiving methadone or actively using heroin. Stigma was assessed using a modified Attribution Questionnaire (mAQ-11), including parenting confidence and custody items. Differences across vignettes, clinical roles, and specialties were analyzed using ANOVA, with P<0.05 considered significant.</p><p><strong>Results: </strong>Among 374 participants (MOUD n=183; heroin use n=191), stigma was significantly higher for active heroin use than the MOUD vignette (mean mAQ-11: 42.53 vs. 34.57, P<0.001). In the heroin-use vignette, clinicians endorsed less stigma than nurses and other medical professionals (P<0.001). Pediatric/neonatal clinicians endorsed greater stigma than obstetric clinicians (P=0.03). MOUD vignette participants expressed greater confidence in parenting ability and support for custody retention (P<0.001).</p><p><strong>Conclusions: </strong>Health care worker stigma toward pregnant people with OUD was greatest in active opioid use vignettes. Differences across clinical roles and specialties identify important targets for antistigma interventions.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nora Anderson, Vanessa M McMahan, Yi-Shin G Chang, Luke N Rodda, Alex H Kral, Phillip O Coffin
{"title":"How Should Stimulant Deaths Be Counted? A Cross-Sectional Analysis of Deaths Attributed to Opioids, Stimulants, or Alcohol.","authors":"Nora Anderson, Vanessa M McMahan, Yi-Shin G Chang, Luke N Rodda, Alex H Kral, Phillip O Coffin","doi":"10.1097/ADM.0000000000001793","DOIUrl":"10.1097/ADM.0000000000001793","url":null,"abstract":"<p><strong>Introduction: </strong>The different ways deaths are counted for surveillance-all attributable to alcohol versus acute toxicity for opioids or stimulants-have profound implications for understanding mortality and deploying prevention interventions.</p><p><strong>Objectives: </strong>To explore alternative strategies to count stimulant (cocaine, psychostimulants) deaths.</p><p><strong>Methods: </strong>We grouped substance-attributable deaths in San Francisco, CA, from 2015 to 2024 into mutually exclusive categories by involved substance (opioids, stimulants, alcohol). We used multivariable Poisson regression to determine prevalence ratios of additional contributing conditions (any, cardiac/hypertensive, or hepatobiliary and pancreatic) for each drug category, adjusted for age, sex, and race/ethnicity. We then used a postestimation technique to calculate adjusted predicted prevalence rates for each group.</p><p><strong>Results: </strong>The adjusted prevalence ratio of any additional conditions was significantly different across substance-attributable death categories (P<0.001). Compared to stimulant deaths, opioid deaths had significantly lower prevalence of additional conditions [adjusted prevalence ratios (aPR): 0.51, 95% CI: 0.48-0.55], while alcohol deaths had higher prevalence (aPR: 1.24, 95% CI: 1.18-1.30). Opioid and alcohol deaths had a lower prevalence of cardiovascular conditions compared to stimulant deaths. Stimulant and alcohol deaths occurred at older ages than opioid deaths.</p><p><strong>Conclusions: </strong>More stimulant- and alcohol-attributable deaths without opioids include complex medical conditions compared to opioid deaths. Counting all attributable stimulant deaths, excluding opioids, may improve our understanding of these deaths and interventions to address health consequences of stimulant use.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisha M Wachman, Scott Wexelblatt, Michelle R Lofwall, Todd H Davies, Martha M Werler, Sorraya Jaiprasert, T John Winhusen
{"title":"Examination of Infant Sex Differences in Neonatal Opioid Withdrawal Syndrome Severity After In-Utero Buprenorphine Exposure in the MOMS Clinical Trial.","authors":"Elisha M Wachman, Scott Wexelblatt, Michelle R Lofwall, Todd H Davies, Martha M Werler, Sorraya Jaiprasert, T John Winhusen","doi":"10.1097/ADM.0000000000001781","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001781","url":null,"abstract":"<p><strong>Objectives: </strong>Neonatal opioid withdrawal syndrome (NOWS) severity is influenced by several clinical factors; however, the association with infant sex is poorly understood. We examined the association between infant sex and NOWS severity in a cohort of buprenorphine-exposed infants.</p><p><strong>Methods: </strong>This was a secondary analysis of the MOMS clinical trial (NCT03918850). Regression models evaluated the association between infant sex and NOWS severity measures, including (1) receipt of any pharmacologic treatment, (2) opioid treatment days, (3) adjunctive medication treatment, (4) length of hospital stay (LOS), and (5) LOS related to NOWS.</p><p><strong>Results: </strong>There were 135 infants (67 male, 68 female). There were no significant differences in demographics or medical comorbidities by infant sex. Methamphetamine and phencyclidine exposures were positively associated with receipt of any pharmacologic treatment, and phencyclidine with longer LOS. Breastfeeding was associated with decreased receipt of any pharmacologic treatment and shorter total LOS, and preterm delivery and NICU admission with longer total LOS. In final regression models, NOWS severity did not differ by infant sex.</p><p><strong>Conclusions: </strong>Infant sex was not statistically associated with NOWS severity measures within this buprenorphine-exposed cohort. Meta-analyses are needed to better understand the relationship between infant sex and NOWS.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carla King, Keith S Goldfeld, Megan Miller, Mishka Terplan, Daniel Schatz, Charles J Neighbors, Jennifer McNeely, Noa Krawczyk
{"title":"Gaps in Addiction Care Among Hospitalized Reproductive-Aged Women With Opioid Use Diagnoses: A Cross-Sectional Study.","authors":"Carla King, Keith S Goldfeld, Megan Miller, Mishka Terplan, Daniel Schatz, Charles J Neighbors, Jennifer McNeely, Noa Krawczyk","doi":"10.1097/ADM.0000000000001791","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001791","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the use of addiction consult services and medications for opioid use disorder (MOUD) among hospitalized reproductive-aged women with opioid use diagnoses, examining reach to pregnant women, women admitted to obstetrics, and across race and ethnicity.</p><p><strong>Methods: </strong>Using electronic health records (2021-2022), we identified admissions among women aged 18-44 with opioid use diagnoses (disorders, poisonings/adverse effects) at 8 New York City public hospitals with addiction consult services. Bayesian hierarchical logistic models estimated associations of being pregnant (vs. not pregnant), admitted to obstetrics (vs. medicine/other departments), and race/ethnicity with consult orders; consult completions; MOUD orders; and MOUD orders among those with completed consults. We report adjusted odds ratios (aOR) and 95% credible intervals (CrIs).</p><p><strong>Results: </strong>Among 547 eligible admissions (388 patients), 11.7% were pregnant and 9.9% were admitted to obstetrics. Patients were Black (23.5%), Hispanic (33.0%), multiracial/other races (13.7%), and White (26.8%). Compared with medicine/other departments, obstetrics patients had lower odds of a consult order (aOR=0.31; 95% CrI: 0.11-0.78). Pregnant patients had lower odds of a consult order compared to nonpregnant patients, though estimates were under uncertainty (aOR=0.53; 95% CrI: 0.21-1.28). Black women had lower odds of a consult order (aOR=0.42; 95% CrI: 0.18-0.96) and MOUD (aOR=0.25; 95% CrI: 0.09-0.71) compared to White women.</p><p><strong>Conclusions: </strong>Findings highlight pregnancy-related differences and racial inequities in addiction consult service and MOUD utilization during hospitalization, underscoring a potential need for stronger obstetrics-addiction collaboration and equity-focused care.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Srinivas B Muvvala, Rebecca Minahan-Rowley, Emma Biegacki, Kenneth L Morford, Ellen L Edens, John Encandela, Jeanette M Tetrault
{"title":"Development of an Interprofessional Teamwork Entrustable Professional Activity for Addiction Medicine and Addiction Psychiatry Fellows.","authors":"Srinivas B Muvvala, Rebecca Minahan-Rowley, Emma Biegacki, Kenneth L Morford, Ellen L Edens, John Encandela, Jeanette M Tetrault","doi":"10.1097/ADM.0000000000001796","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001796","url":null,"abstract":"<p><strong>Background: </strong>Substance-use disorders (SUD) require collaborative, multi-specialty care. While graduate medical education (GME) fellowships in addiction medicine (AM) and addiction psychiatry (AP) prepare trainees for interprofessional collaborative care, standard Accreditation Council for Graduate Medical Education milestones lack a mechanism to directly observe and assess competence in providing interprofessional team-based care.</p><p><strong>Objective: </strong>To develop and pilot an entrustable professional activity (EPA) focused on interprofessional team-based care applicable to both AM and AP fellowships.</p><p><strong>Methods: </strong>Using a systematic 3-step consensus process, a multidisciplinary faculty team mapped overlapping AM and AP milestones across 6 Accreditation Council for Graduate Medical Education core domains to identify those related to interprofessional work. Key functions and a scoring instrument to measure them were developed by an iterative consensus process. The team then drafted an Interprofessional EPA listing foundational milestones and related functions alongside descriptions of expected behaviors at 3 developmental levels.</p><p><strong>Results: </strong>The EPA was piloted with faculty and fellows. Initial implementation faced barriers regarding faculty uptake due to competing demands. Based on faculty feedback, the EPA was transitioned from a summative scale to a formative tool utilizing narrative summaries to enhance real-time feedback and support milestone reporting.</p><p><strong>Conclusions: </strong>This EPA provides a structured approach to assess essential, observable interprofessional clinical skills. By shifting to a formative framework, the tool facilitates low-stakes feedback and fosters cross-disciplinary learning. As there is a national push to incorporate EPAs into trainee assessments, this process can inform other residency and fellowship training programs nationally in implementing similar frameworks.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simon J Ostrowski, Kory S London, James Travis Donahoe, Michael J Lynch
{"title":"Medetomidine: Dose-Response Approach to Drug Monitoring.","authors":"Simon J Ostrowski, Kory S London, James Travis Donahoe, Michael J Lynch","doi":"10.1097/ADM.0000000000001794","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001794","url":null,"abstract":"<p><p>Drug supply monitoring programs commonly describe novel substances in binary terms: a substance is either present or absent, and its presence alone defines risk. Medetomidine, a veterinary imidazole alpha-2 agonist anesthetic, has been detected as an adulterant in illegally manufactured fentanyl across the United States, and reports of medetomidine toxicity have been similarly widespread. Yet its severe withdrawal syndrome has emerged in communities more gradually, with many unaffected. The environmental-health concept of dose-response offers a plausible explanation for this geographic mismatch. Some harms follow a linear relationship where any exposure carries risk, and that risk rises in proportion to dose. Opioid overdose and medetomidine toxicity fit this pattern. Others may follow a threshold relationship, appearing only once exposure surpasses a critical level. Medetomidine withdrawal fits the threshold pattern because tolerance, and therefore withdrawal, require sustained exposure of sufficient dose and duration. Where it has appeared, the withdrawal syndrome has strained local hospital systems. Preliminary review of hospital billing data and community drug-checking results suggests that hospital utilization rose only after medetomidine's prevalence and potentially concentration in the local supply crossed a threshold. Current evidence supporting application of this dose-response theory to medetomidine withdrawal is hypothesis-generating. Further work linking drug-supply prevalence and concentration data to well-defined, drug-specific clinical outcomes could support a surveillance system that lets public health and hospital stakeholders anticipate drug-related harms before they become widespread, using evidence-based thresholds.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ynhi T Thomas, Mubeen Iqbal, Chung Jung Mun, Carlos A Zamarripa, Thomas R Kosten, Frank Vocci, Rachel Bobb, Faiez Samad, Christopher D Verrico
{"title":"Advancing Kratom Science and Regulation: A Comparative Framework With Cannabis.","authors":"Ynhi T Thomas, Mubeen Iqbal, Chung Jung Mun, Carlos A Zamarripa, Thomas R Kosten, Frank Vocci, Rachel Bobb, Faiez Samad, Christopher D Verrico","doi":"10.1097/ADM.0000000000001728","DOIUrl":"10.1097/ADM.0000000000001728","url":null,"abstract":"<p><p>Kratom ( Mitragyna speciosa ) is a psychoactive botanical with a long history of use in Southeast Asia and growing uptake in the United States for its analgesic, stimulant, and mood-altering properties. The evidence base remains limited, and retail products vary widely in composition and potency. This narrative review highlights what is known about kratom's pharmacology and suggests a practical research and regulatory path toward evaluating its potential therapeutic applications within current regulatory frameworks, based on lessons from cannabis. A central distinction is between whole leaf products and those that are enriched in active constituents or that include semisynthetic derivatives. Because these categories differ in chemistry, pharmacology, and expected risk, they require different evidence standards. Priorities include development of chemically defined botanical preparations, validated analytical methods, and human studies that link exposure to effect through pharmacokinetic and pharmacodynamic modeling, abuse liability assessment, and cognitive and behavioral testing. The regulatory framework for kratom should consider a dual track. This includes enhanced standards for product quality, including composition, purity, labeling, and safety surveillance for botanical products, and conventional drug development pathways for enriched or semisynthetic constituents that include toxicology and human abuse potential studies. Coordinated federal support is urgently needed to align product standardization, early phase trials, and comparative evaluations across product classes. With this structure, kratom's possible therapeutic applications can be examined while safeguarding public health.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"e223-e229"},"PeriodicalIF":3.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}